Patents by Inventor Michael Kaleko

Michael Kaleko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20220098566
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: December 8, 2021
    Publication date: March 31, 2022
    Inventors: Michael KALEKO, Sheila CONNELLY
  • Beta-lactamases with improved properties for therapy
    Patent number: 11236319
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: February 1, 2022
    Assignee: Synthetic Biologies, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • CARBAPENEMASES FOR USE WITH ANTIBIOTICS FOR THE PROTECTION OF THE INTESTINAL MICROBIOME
    Publication number: 20220000991
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: August 19, 2021
    Publication date: January 6, 2022
    Inventors: Michael KALEKO, Sheila CONNELLY
  • E. COLI-BASED PRODUCTION OF BETA-LACTAMASE
    Publication number: 20210332373
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Application
    Filed: May 7, 2021
    Publication date: October 28, 2021
    Inventors: Andrew BRISTOL, Michael KALEKO, Steven HUBERT
  • STABILIZED PERTUSSIS ANTIBODIES WITH EXTENDED HALF-LIFE
    Publication number: 20210332112
    Abstract: The present invention relates, in part, to modified humanized antibodies which bind the pertussis toxin protein and their use as therapeutic agents. In particular, the present invention is directed, in part, to improved humanized 1B7 and 11E6 antibodies with extended in vivo half-lives.
    Type: Application
    Filed: August 15, 2017
    Publication date: October 28, 2021
    Inventors: Jennifer MAYNARD, Annalee NGUYEN, Michael KALEKO
  • Carbapenemases for use with antibiotics for the protection of the intestinal microbiome
    Patent number: 11123413
    Abstract: This invention relates, in part, to various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 21, 2021
    Assignee: Synthetic Biologies, Inc.
    Inventors: Michael Kaleko, Sheila Connelly
  • MICROBIOME PROTECTION FROM ORAL ANTIBIOTICS
    Publication number: 20210220452
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.
    Type: Application
    Filed: June 28, 2017
    Publication date: July 22, 2021
    Inventors: Michael KALEKO, Sheila CONNELLY
  • ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20210220448
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Application
    Filed: March 29, 2021
    Publication date: July 22, 2021
    Inventors: Vincent WACHER, J. Blair WEST, Michael KALEKO, Christian FURLAN FREGUIA
  • METHODS OF MAKING ALKALINE PHOSPHATASE AGENTS
    Publication number: 20210189358
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment of disease, such as microbiome-related diseases. In part, the invention provides, in various embodiments, methods of manufacturing therapeutic alkaline phosphatases.
    Type: Application
    Filed: June 17, 2019
    Publication date: June 24, 2021
    Inventors: Maria RODRIGUES, Veronique DE VAUX, Michael KALEKO
  • -based production of beta-lactamase
    Patent number: 11034966
    Abstract: The invention relates to, in part, improved methods for the production of beta-lactamase using Escherichia coli (E. coli) cells. High yield production of beta-lactamase is achieved using methods of the invention.
    Type: Grant
    Filed: August 27, 2015
    Date of Patent: June 15, 2021
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Steven Hubert
  • Complement factor B analogs and their uses
    Patent number: 11001822
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: May 11, 2021
    Assignee: Wellstat ImmunoTherapeutics, LLC
    Inventors: ChangHung Chen, Michael Kaleko, Beibei Li, Tianci Luo, Jeffrey Allan Miller, Ruigong Wang
  • Alkaline phosphatase formulations
    Patent number: 10987410
    Abstract: The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: April 27, 2021
    Assignee: Synthetic Biologics, Inc.
    Inventors: Vincent Wacher, J. Blair West, Michael Kaleko, Christian Furlan Freguia
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF NEURODEVELOPMENTAL DISORDERS
    Publication number: 20210060139
    Abstract: The present invention relates, inter alia, to compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders.
    Type: Application
    Filed: January 8, 2019
    Publication date: March 4, 2021
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • INTESTINAL ALKALINE PHOSPHATASE FORMULATIONS
    Publication number: 20210030686
    Abstract: The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.
    Type: Application
    Filed: March 20, 2019
    Publication date: February 4, 2021
    Inventors: Andrew BRISTOL, Ray STAPLETON, Michael KALEKO, Christian FURLAN FREGUIA, Steven HUBERT, Cristina FREIRE, James GUBBINS
  • ALKALINE PHOSPHATASE AGENTS FOR TREATMENT OF RADIATION DISORDERS
    Publication number: 20210023182
    Abstract: The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.
    Type: Application
    Filed: March 20, 2019
    Publication date: January 28, 2021
    Inventors: Michael KALEKO, Christian FURLAN FREGUIA, Sheila CONNELLY
  • BETA-LACTAMASE FORMULATIONS AND USES THEREOF
    Publication number: 20210007994
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Application
    Filed: September 28, 2020
    Publication date: January 14, 2021
    Inventors: Andrew BRISTOL, Michael KALEKO, Sheila CONNELLY
  • METHOD AND COMPOSITIONS FOR INHIBITING OR PREVENTING ADVERSE EFFECTS OF ORAL ANTIBIOTICS
    Publication number: 20200384092
    Abstract: This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.
    Type: Application
    Filed: August 20, 2020
    Publication date: December 10, 2020
    Inventors: Michael KALEKO, Sheila CONNELLY, Vincent John WACHER
  • Beta-lactamase formulations and uses thereof
    Patent number: 10828260
    Abstract: The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: November 10, 2020
    Assignee: Synthetic Biologics, Inc.
    Inventors: Andrew Bristol, Michael Kaleko, Sheila Connelly
  • BETA-LACTAMASES WITH IMPROVED PROPERTIES FOR THERAPY
    Publication number: 20200347375
    Abstract: This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such as C. difficile infection (CDI).
    Type: Application
    Filed: July 24, 2020
    Publication date: November 5, 2020
    Inventors: Michael KALEKO, Sheila CONNELLY
  • Complement Factor B Analogs and Their Uses
    Publication number: 20200325464
    Abstract: The invention provides polypeptides comprising a complement factor B analog. The invention also provides various complement factor B analogs including complement factor B analogs comprising a mutation of a free cysteine amino acid and related methods, nucleic acids and vectors. These complement factor B analogs and related methods, nucleic acids and vectors can be used to modulate a complement pathway or for the study and/or treatment of various conditions or diseases related to a complement pathway.
    Type: Application
    Filed: May 14, 2020
    Publication date: October 15, 2020
    Inventors: ChangHung CHEN, Michael KALEKO, Beibei Li, Tianci LUO, Jeffrey Allan MILLER, Ruigong WANG